Abstract
Pyoderma gangrenosum (PG) is an ulcerating noninfectious disease of the skin seen in 1 to 5% of patients with inflammatory bowel disease. The pathogenesis of PG has yet to be determined but may be related to abnormal T cell responses and the production of TNF-α, a powerful proinflammatory cytokine. Infliximab, a chimeric monoclonal antibody to TNF-α, has been approved for the treatment of Crohn's disease. We present four patients with PG treated with Infliximab for fistulizing Crohn's in whom complete healing of PG was achieved. Four patients with active fistulizing Crohn's disease and PG were treated. All patients were females ranging in age from 48 to 60 years, with a mean age of 54 years. Three of four patients had PG lesions located on the lower extremities; one patient had peristomal disease. All patients had at least colonic involvement of their Crohn's. The patients received either a single infusion or a series of three 5 mg/kg Infliximab infusions. All four patients demonstrated rapid healing of PG within 4 weeks of the first infusion of Infliximab. PG healing followed improvement in bowel disease. Complete resolution without recurrence was noted in all patients. Rapid resolution of PG was noted in four female patients with fistulizing Crohn's disease treated with Infliximab. Healing was complete, without recurrence. The anti-TNF-α properties of Infliximab suggest that healing may be mediated by the drug's effect on cytokine pathways, perhaps by blunted T cell activation early in the inflammatory cascade. We suggest an independent effect of Infliximab on PG.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Powell FC, Su WPD, Perry HO: Pyoderma gangrenosum: Classification and management. J Am Acad Dermatol 34(3):395–409, 1996
Brian G, Ho VC: Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 23(3):371–383, 1992
Brunsting LA, Goeckerman WH, O'Leary PA: Pyoderma gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol 22:655–680, 1930
Lebowhl M, Lebwohl O: Cutaneous manifestations of inflammatory bowel diseases. Inflam Bowel Dis 4(2):142–148, 1988
Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 70(3):439–444, 1976
Adachi Y, Kindzelskii AL, Cookingham G, Shaya S, Moore EC, Todd RF, Petty HR: Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol 111(2):259–268, 1998
Robert C, Kupper TS: Inflammatory skin diseases, T cells and immune surveillance. N Engl J Med 341(24):1817–1828, 1999
Powell FC, Perry HO: Pyoderma gangrenosum in childhood. Arch Dermatol 120:757–761, 1984
Greenstein AJ, Janowitz HD, Sachar DB: The extra-intestinal complications of Crohn's disease and ulcerative colitis: A study of 700 patients. Medicine 55(5):401–412, 1976
Burgdorf W: Cutaneous manifestations of Crohn's disease. J Am Acad Dermatology 5:689–695, 1981
Katz SK, Gordon KB, Roenigk HH: The cutaneous manifestations of gastrointestinal disease. Primary Care 23(3):455–476, 1996
Mountain JC: Cutaneous ulceration in Crohn's disease. Gut 11:18–26, 1970
Paller AS: Cutaneous changes associated with inflammatroy bowel disease. Pediatr Dermatol 3(6):439–445, 1986
Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC: Twenty cases of peristomal pyoderma gangrenosum: Diagnostic implications and management. Arch Surg 135(5):564–568, 2000
Hughes AP, Jackson JM, Callen JP: Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 284(12):1546–1548, 2000
Powell R, Holbrook M, Stevens A: Pyoderma gangrenosum and its treatment. Lancet 350:1720–1721, 1997
Levitt MD, Ritchie JK, Lennard-Jones JE, Phillips RK: Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 78(6):676–678, 1991
Goldstein F, Krain R, Thornton JJ: Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol 7(6):499–501, 1985
Friedman S, Marion JF, Scherl E, Rubin PH, Present DH: Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflam Bowel Dis 7(1):1–7, 2001
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action of tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177(6); 1675–1680, 1993
Faure M, Thivolet J, Gaucherand M: Inhibition of PMN leukocytes chemotaxis: Inhibition by thalidomide. Arch Dermatol Res 269(3):275–280, 1980
Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J exp med 173(3):699–703, 1991
Federman GL, Federman DG: Recalcitrant pyoderma gangrensoum treated with thalidomide, Mayo Clin Proc 75(8):842–844, 2000
Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ: Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116(1):22–28, 1999
Hong JJ, Merel NJ, Hanauer SB: Treatment of pyoderma gangrenosum (PG) complicating Crohn's disease (CD) with Infliximab. Gastroenterology A621:3143, 2001 (abstr)
Daoud MS, Lust, JA, Kyle RA, Pittelkow MR: Monoclonal gammopathies and associated skin disorders. J Am Acad Dermatol 40:507–535, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sapienza, M.S., Cohen, S. & Dimarino, A.J. Treatment of Pyoderma Gangrenosum with Infliximab in Crohn's Disease. Dig Dis Sci 49, 1454–1457 (2004). https://doi.org/10.1023/B:DDAS.0000042245.20042.4f
Issue Date:
DOI: https://doi.org/10.1023/B:DDAS.0000042245.20042.4f